

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Method for determining predisposition to a venous thromboembolic disease

5 The present invention is based on the demonstration of a close link between infection with a bacterium of the Chlamydia genus and venous thromboembolic disease.

10 The invention more particularly relates to a method for determining, *in vitro*, predisposition to a venous thromboembolic disease in an individual, in which it is determined whether the individual has been infected with a bacterium of the Chlamydia genus, and to the use of agents active on bacteria of the Chlamydia genus, for preventing and/or treating a venous thromboembolic  
15 disease.

Venous thromboembolic disease is a multifactor disorder with both genetic and acquired risk factors (Rosendaal et al., 1997). Conventional risk factors for venous  
20 thrombosis are associated with modification of the vessels or stasis (slowing down, or even stopping of venous blood circulation), due in particular to a trauma, a surgical operation or immobilization. Overall, genetic predisposition to venous thrombosis  
25 explains only 40% of cases. Deficiencies in antithrombin, in protein C and in protein S explain in particular 5 to 10% of cases of venous thromboembolic diseases. After having taken into account conventional acquired risk factors and genetic predispositions, at  
30 least a third of venous thrombotic episodes remain unexplained.

Currently, the most commonly used treatment in cases of venous thrombosis is treatment based on anticoagulants.  
35 However, such a treatment can be envisioned only for a limited period of time, because of dangerous side effects. Prolonged administration of anticoagulants in fact increases the risks of hemorrhages, in particular

cerebral hemorrhages. Consequently, an alternative treatment is sought.

5 The link between infection with *Chlamydia pneumoniae* and atherosclerosis is well documented. The use of antibiotics in the treatment of cardiovascular diseases, such as myocardial infarction or coronary artery diseases, has also been envisioned (WO 90/00061, WO 98/17280, WO 98/06408, Gibbs et al., 1998). The  
10 cardiovascular diseases targeted are, however, diseases of the arterial system.

On the other hand, to date, no datum would suggest the possibility of a link between *Chlamydia pneumoniae* and  
15 the pathologies of the venous system. Although an article by Ong et al., published in 1996, reported the detection by PCR (polymerase chain reaction) of *Chlamydia pneumoniae* in an iliac vein on two control individuals a priori free of pathological vascular  
20 conditions, a subsequent article (Bartels et al., 1998) reported, on the contrary, the absence of this bacterium in the native saphenous veins of patients who had undergone a coronary bypass.

25 The authors of the present invention have discovered, surprisingly, a close link between infection with a bacterium of the *Chlamydia* genus and a venous thromboembolic disease.

30 More particularly, the authors of the invention have shown that high levels of anti-*Chlamydia pneumoniae* antibodies represent a risk factor for a venous thromboembolic disease.

35 Without in any way associating themselves with a precise mechanism of action, the authors are putting forward the hypothesis that chronic infection of the vein walls with *Chlamydia pneumoniae* may render the venous endothelial cells thrombogenic.

A subject of the present invention is therefore a method for determining, *in vitro*, predisposition to a venous thromboembolic disease in an individual, in  
5 which it is determined whether the individual has been infected with a bacterium of the *Chlamydia* genus, more particularly *Chlamydia pneumoniae*.

It is determined whether the individual has been  
10 infected with a bacterium of the *Chlamydia* genus by analyzing a biological sample. It may in particular be a sample of blood, of urine or of pleural liquid, a sample obtained by bronchoscopy or by bronchoalveolar lavage, or a sample obtained by biopsy, for example of  
15 the vascular endothelium. It is then possible to determine whether this sample contains anti-*Chlamydia* antibodies or whether it contains bacteria of the *Chlamydia* genus or fragments thereof. It is, for example, possible to search for the presence of a  
20 chlamydial component, such as liposaccharides or membrane-bound proteins, of substances produced by *Chlamydia*, such as exopolysaccharides, or of substances produced by the host cells via *Chlamydia* induction.

25 Preferably, it is determined whether the individual has been infected with a bacterium of the *Chlamydia* genus, by assaying the level of anti-*Chlamydia* antibodies in a biological sample from an individual to be tested, for example a blood sample.

30 The anti-*Chlamydia* antibody titers obtained in the individuals to be tested are then compared with the antibody titers obtained in control individuals. The titer is defined by the maximum dilution of the  
35 biological sample for which the antibodies are still detected, and is expressed by the inverse of the dilution factor. An antibody titer of greater than 256 may be considered to represent a not insignificant risk factor.

A subject of the present invention is therefore, more particularly, a method for determining predisposition to a venous thromboembolic disease in an individual, comprising the steps consisting in:

- i) assaying the level of anti-chlamydia antibodies in a biological sample from an individual to be tested;
- ii) comparing this level of antibodies with the level of anti-chlamydia antibodies obtained in control individuals;
- iii) identifying the individual tested as an individual exhibiting predisposition to a venous thromboembolic disease if the level of antibodies obtained in step i) is greater than the level of anti-chlamydia antibodies obtained in control individuals.

The present invention also relates to the use of at least one agent active against infection with a bacterium of the *Chlamydia* genus, in particular *Chlamydia pneumoniae*, or of at least one agent effective against the inflammatory effects of infection with *Chlamydia*, for preventing and/or treating a venous thromboembolic disease.

Preferably, pharmaceutical compositions containing antibiotic agents may be used.

A subject of the invention is therefore more particularly the use of an antibiotic substance active on bacteria of the *Chlamydia* genus, in particular *Chlamydia pneumoniae*, for preparing a medicinal product intended to prevent and/or treat a venous thromboembolic disease.

Among the antibiotic substances or agents active on the bacterial genus *Chlamydia*, mention may in particular be made of macrolides (for example erythromycin or azithromycin), tetracyclines, fluoroquinolones and

rifampicin.

According to another embodiment of the present invention, said agent active against infection with  
5 *Chlamydia* may be an immunogenic protein, or an immunogenic fragment of a protein, of *Chlamydia*, in particular of *Chlamydia pneumoniae*. These proteins, or these protein fragments, are characterized by their ability to induce cell-mediated or humoral immunity  
10 against infection with *Chlamydia*, in particular *Chlamydia pneumoniae*, by administration of the protein in combination with a suitable adjuvant. Preferably, use may be made of the major outer membrane protein or cell surface proteins from the bacterium, which may be  
15 randomly fragmented. The random fragments of a *Chlamydia* protein can be tested for their immunogenicity by those skilled in the art. Vaccines containing cellular antigens of *Chlamydia* [lacuna] fragments thereof may be obtained conventionally, for  
20 example by cell lysis or using standard purification or separation techniques.

A composition which can be used according to the invention may also comprise a *Chlamydia* bacterium which  
25 has been killed or inactivated by any conventional means, such as heat or irradiation.

A composition which can be used according to the present invention may also contain one or more nucleic  
30 acid sequences encoding a surface protein of *Chlamydia* or a fragment thereof. The nucleic acid used may be administered using an immunization vector or in naked form, i.e. free of any agent which facilitates the penetration of this nucleic acid into the cell.

35

A subject of the invention is also a method for preventing and/or treating venous thromboembolic disease, in which a prophylactically or therapeutically effective amount of an agent active on bacteria of the

Chlamydia genus, in particular of an antibiotic agent, in combination with a pharmaceutically acceptable vehicle, is administered to a patient requiring such a treatment.

5

The prevention of recurrences subsequent to a first venous thrombosis is more particularly targeted.

10

The methods of an administration, the doses and the pharmaceutical forms of the pharmaceutical compositions which can be used according to the invention may be determined in the usual way by those skilled in the art, in particular according to the criteria generally taken into account in establishing a therapeutic treatment suitable for a patient, such as for example the age or body weight of the patient, the seriousness of his or her general condition, the tolerance to the treatment and the side effects noted, etc.

15

20

A pharmaceutical composition which can be used according to the invention may in particular be administered orally, parenterally, intravenously, intramuscularly, subcutaneously, percutaneously or intranasally.

25

30

When the pharmaceutical composition used is an antibiotic composition, the effective dose lies within the ranges conventionally used for any antibiotic against Chlamydia bacteria. Said composition may in particular be advantageously administered in short cycles (4 to 10 days approximately), to be repeated, for example, every six months after the first venous thrombotic episode.

35

The link between infection with a *Chlamydia pneumoniae* bacterium and a venous thromboembolic disease is illustrated in the results presented hereinafter, which in no way limit the scope of the present invention.

The authors of the present invention have thus studied 176 patients with a diagnosed venous thromboembolic disease and 197 control individuals in good health, of various age and sex. The acquired risk factors for a venous thromboembolic disease and the common genetic predisposition factors (Arg 506 Gln mutation in factor V and G 20210 A mutation in factor II) were evaluated in all the individuals. The level of anti-*C. pneumoniae* IgG antibodies was determined by microimmuno-fluorescence. All the positive plasma samples (titer  $\geq$  128) were accurately quantified and tested for the presence of specific IgM antibodies.

#### MATERIALS AND METHODS:

##### *Individuals:*

The patients less than 61 years old who had had at least one episode of deep vein thrombosis diagnosed objectively (compression ultrasonography or venography) and/or a pulmonary embolism (ventilation and perfusion pulmonary scintigraphy, conventional pulmonary angiography and a spiral scan) were selected from 205 patients (92 men and 113 women) with venous thromboembolic diseases. A complete clinical study was carried out on all the patients, emphasizing their personal and family histories regarding thromboembolic disease, and the acquired risk factors (surgery or trauma within the last three months, immobilization for longer than 72 hours, pregnancy, treatment with estrogens, varicose veins and cancer). Blood was taken from 176 patients (86%); in 87 cases, samples were obtained less than three months after an acute venous thromboembolic disease had been triggered (median 1 day; IQR deviation 0-16), whereas the remaining 89 samples were obtained more than three months after triggering (median 12 months, IQR deviation 6.5-36). The 197 healthy control individuals of varied age and sex were selected as having no history of venous



thromboembolic disease, of myocardial infarction or of peripheral vascular disease.

Assay:

5

The venous blood was collected in 0.129 M trisodium citrate (1:10) and two steps of centrifugation at 2000 g for 15 minutes were carried out in order to obtain a platelet-depleted plasma. The plasma was frozen and stored in aliquot fraction form at -40°C until use. The DNA was extracted from the leukocytes using standard methods and stored at 4°C.

10

For the serological tests, each case and each control sample were labeled with a random number and analyzed blind. The serological status in terms of *C. pneumoniae* was determined by a microimmunofluorescence (MIF) assay using the "SeroFIA IgG Chlamydia" kit (Savyon Diagnostics Ltd., Ashdod, Israel). Briefly, elementary bodies of purified *C. pneumoniae* (IOL 207 strain) were used to detect the IgG antibodies. All the plasma samples were initially screened at a dilution of 1:128 and were considered to be positive above this dilution. The positive plasmas were then tested at dilutions of 1:256, 1:512 and 1:1024. The specific IgG titers were given as the inverse of the final positive dilution. Samples positive for anti-*C. pneumoniae* IgGs were then tested for the presence of anti-*C. pneumoniae* IgMs using the MIF assay with the "SeroFIA IgM Chlamydia" kit (Savyon Diagnostics Ltd), at a dilution of 1:20 as recommended by the manufacturer.

25

30

A study was, moreover, carried out to determine whether the DNA of the control individuals and of the patients exhibited the Arg 506 Gln mutation in factor V, after PCR amplification of exon 10 of factor V and digestion with restriction enzymes. The transition G 20210 A of the prothrombin gene was identified after amplification using two primers:

35

(5'-TTACAAGCCTGATGAAGGGA-3'  
and 5'-CCATGAATAGCACTGGGAGCATTGAAGC-3'). The second  
primer was constructed such that a nucleotide  
substitution (C to A) at position 20210 creates a new  
5 restriction site for *Hind III* when the transition of G  
to A at position 20210 is present.

*Statistical analysis:*

10 The data are analyzed using the SAS statistical program  
(Institute Inc., Cary, N.C.). The clinical  
characteristics of the entire population of patients  
and of the subgroup of cases with blood samples taken  
less than three months after the episode of thrombosis  
15 were compared to those of the control individuals using  
a  $\chi^2$  test with one degree of freedom. Age was tested  
using analysis of variance (ANOVA).

The odds ratios associated with seropositivity for *C.*  
20 *pneumoniae* were calculated by comparing the individuals  
having titers of 256 or more having individuals with  
titers of less than 256. The heterogeneity of the odds  
ratios in terms of age and sex was tested by entering  
the interaction variables (one degree of freedom) into  
25 logistic regressions. The odds ratios for a venous  
thromboembolic disease and the 95% confidence interval  
(CI) associated with each anti-*C. pneumoniae* IgG titer,  
coded as binary variables, were then calculated with  
reference to seronegativity using a logistic regression  
30 procedure (SAS-PROC LOGIST). The same analysis was  
applied to the subgroup of cases with blood samples  
taken less than three months after the venous  
thromboembolic disease had been triggered. In the  
entire population tested, the levels of seropositivity  
35 for *C. pneumoniae* were compared in terms of first  
thrombosis against recurrent thrombosis, in terms of  
presence of associated risk factor against absence of  
associated risk factor, and in terms of first  
thrombosis at under 40 years of age (median age of the

population) against first thrombosis at over 40 years of age, using a  $\chi^2$  test with one degree of freedom. The differences with values  $p$  less than 0.05 were considered to be significant.

5

### RESULTS:

10 The cases and controls do not differ in terms of age ratios or sex ratios (cf. table 1). Venous thromboembolic disease was considered to be idiopathic in patients who had not been taking any oral  
15 contraception, who had not recently had surgery (less than one month), who had not suffered any trauma, who had not been pregnant or given birth, who had not been immobilized or who had not suffered from cancer. Half of the patients were recruited within three months after the acute episode of venous thrombosis. The characteristics of this subgroup were not statistically different from those of the entire population of cases.  
20 The prevalence of the Arg 506 Gln mutation of factor V and the G 20210 A mutation of factor II was within the range expected in caucasians (21.9% in the patients and 5.1% in the controls,  $p < 0.0001$ ; and 10.2% and 4.1%,  $p = 0.02$ , respectively).

25

The *C. pneumoniae*-specific IgG titers tend to be higher in the patients than in the controls (cf. table 2). Significantly, it is observed that more patients than controls have *C. pneumoniae* IgG titers of 256 or more  
30 (54% and 15.9% respectively,  $p < 0.0001$ ). The odds ratio for the venous thromboembolic diseases associated with IgG titers of 256 or more was 6.2 (95% confidence interval (CI), 3.8-10.1). In the subgroup of patients with blood samples taken less than three months after  
35 the thrombotic episode, the crude ratio (odds ratio) among the individuals with IgG titers  $\geq 256$  was 5.4 (95% CI, 3.1-9.6). In addition, the odds ratio for a venous thromboembolic disease increases with the IgG titer: for titers of 256, 512 and 1024, the crude odds ratios

were 2.1 (95% CI, 1.0-4.2), 4.3 (2.1-8.9) and 32.4 (4.2-248.3), respectively (cf. table 3). A greater proportion of seropositive controls had a low IgG titer of 128 compared to the controls (54.9% and 21%, respectively). Similar odds ratios were obtained in the subgroup of cases tested within three months after the thrombotic episode.

The odds ratios were not significantly different according to age or sex. After exclusion of the individuals bearing the Arg 506 Gln mutation of factor V and the G 20210 A mutation of factor II, the odds ratios for the venous thromboembolic disease associated with a titer greater than 256 was 7.7 (95% CI, 4.5-13.2). The characteristics of the venous thromboembolic disease (age at the time of the first episode; recurrent or spontaneous nature) did not differ as a function of the serological status for *C. pneumoniae*.

In order to distinguish an acute infection from a chronic infection, the authors of the invention also evaluated the circulating anti-*C. pneumoniae* IgM antibodies in the 95 cases and 31 controls who had IgG titers greater than 256. Only one individual from the group of patients suffering from venous thromboembolic diseases was positive for IgMs.

#### **CONCLUSION:**

The results above clearly show a link between the serological status for *C. pneumoniae* and venous thrombosis. The odds ratio for a venous thromboembolic disease associated with circulating titers of anti-*C. pneumoniae* IgG antibodies of 256 or more was 6.2 (95% CI; 3.8-10.1) and remained high after exclusion of the patients with an Arg 506 Gln mutation in factor V and a G 20210 A mutation in factor II (odds ratio 7.7; 95% CI; 4.5-13.2). The fact that the odds ratio for a venous thromboembolic disease increases with the IgG

antibody titer reinforces this association (cf. table 3).

Cases n=176	Controls n=197	Test
% women	55.3	p=0.87
Mean age (SD)	42.9 (10.6)	p=0.92
% oral contraception in women		
34.0	22.0	p=0.053
% FV mutation-Arg 506Gln	5.1	p<0.0001
% FII mutation-G20210A	4.1	p=0.02
% spontaneous TED	-	-
% recurrent TED	-	-
% pulmonary embolism	-	-
Mean age at first TED (SD)	-	-
38.4 (12.0)		

TED: venous thromboembolic disease

SD: standard deviation

Table 1: Characteristics of the cases with a venous thromboembolic disease (TED) and of the controls.

C. pneumoniae IgG titers	Controls n(%)	All cases n(%)	Cases < 3 months*	
			OR(95% CI)	n(%) OR(95% CI)
Negative	57(29.2)	44(25.0)		26(29.9)
128	107(54.9)	37(21.0)		17(19.5)
256	17(8.7)	27(15.4)		14(16.1)
512	13(6.7)	43(24.4)	6.2(3.8-10.1)** p<0.0001	5.4(3.1-9.6)** p<0.0001
1024	1(0.5)	25(14.2)		20(23.0) 10(11.5)

\*Cases with blood samples taken within three months after the TED episode.

\*\* <256 vs ≥256

CI: confidence interval

OR: odds ratio

Table 2: Detection and titration of anti-Chlamydia pneumoniae IgG antibodies in the cases and controls, and odds ratios (95% CI) for a venous thromboembolic disease (TED) associated with IgG titers ≥256

C. pneumoniae IgG titers	All cases			Cases < 3 months*		
	OR	(95% CI)	p	OR	(95% CI)	p
Negative	1	-	-	1	-	-
128	0.4	(0.3-0.8)	0.004	0.3	(0.2-0.7)	0.0028
256	2.1	(1.0-4.2)	0.05	1.8	(0.8-4.2)	0.17
512	4.3	(2.1-8.9)	<0.0001	3.4	(1.5-7.8)	0.0045
1024	32.4	(4.2-248.3)	0.0008	21.9	(2.7-180.3)	0.0041

\*Cases with blood samples taken within three months after the TED episode

CI: confidence interval

OR: odds ratio

Table 3: Odds ratios (95% CI) for a venous thromboembolic disease (TED) as a function of the anti-*Chlamydia pneumoniae* IgG titers with reference to the absence of detectable antibodies.



REFERENCES

- 5        -     Bartels C. et al. Detection of Chlamydia  
         pneumoniae but not cytomegalovirus in occluded  
         saphenous vein coronary artery bypass grafts.  
         Circulation, 1999, 99:879-882.
- 10       -     Gibbs RGJ, Carey N, Davies AH. Chlamydia  
         pneumoniae and vascular disease. Br J Surg 1998;  
         85:1191-7.
- 15       -     Ong G, Thomas BJ, Mansfield AO, Davidson BR,  
         Taylor-Robinson D. Detection and widespread  
         distribution of Chlamydia pneumoniae in the  
         vascular system and its possible implications. J.  
         Clin Pathol 1996; 49:102-6.
- 20       -     Rosendaal FR. Thrombosis in the young:  
         epidemiology and risk factors. A focus on venous  
         thrombosis. Thromb Haemost 1997; 78:1-6.

25